European Event-Driven Analyst

Jesus Rodriguez Aguilar

Event-Driven

<ul>
<li>May saw selective convergence reassert itself across Europe’s dual-class universe, with broad tightening in several structurally wide and liquidity-driven spreads offsetting renewed widening in Carlsberg and Grifols.</li>
<li>Both median and mean tightened, confirming no systemic repricing of voting rights. Dispersion remains driven by liquidity, concentrated ownership, implementation constraints and episodic positioning reversals across Europe’s dual-class universe.</li>
<li>Handelsbanken, Media-for-Europe and Telecom Italia delivered the strongest tightening moves in May, while Carlsberg and Grifols reversed sharply, re-widening after April’s convergence phase.</li>
</ul>


May saw selective convergence reassert itself across Europe’s dual-class universe, with broad tightening in several structurally wide and liquidity-driven spreads offsetting renewed widening in Carlsberg and Grifols.
Both median and mean tightened, confirming no systemic repricing of voting rights. Dispersion remains driven by liquidity, concentrated ownership, implementation constraints and episodic positioning reversals across Europe’s dual-class universe.
Handelsbanken, Media-for-Europe and Telecom Italia delivered the strongest tightening moves in May, while Carlsberg and Grifols reversed sharply, re-widening after April’s convergence phase.


Liquid Universe of European Ordinary and Preferred Shares: May '26 Report

Asia Healthcare Analyst, Pathology Associates Limited

Dion Stéfan Büchner M.D., FCAP

Asia Healthcare Analyst

Pathology Associates Limited

Thematic (Sector/Industry)

AML represents one of the largest hematologic cancer populations with one of the worst survival rates. Global prevalence is expected to increase at 2015-20 CAGR of ~12% to 434,214 in 2020.The current standard of care for newly diagnosed patients is a combination of daunorubicin and cytarabine, commonly known as 7+3. However, durable remissions occur only in a minority of adult patients. Hence r/r AML remains a disease of high unmet need, especially for “elderly” patients. Treatment landscape…

AML represents one of the largest hematologic cancer populations with one of the worst survival rates. Global prevalence is expected to increase at 2015-20 CAGR of ~12% to 434,214 in 2020.The current standard of care for newly diagnosed patients is a combination of daunorubicin and cytarabine, commonly known as 7+3. However, durable remissions occur only in a minority of adult patients. Hence r/r AML remains a disease of high unmet need, especially for “elderly” patients. Treatment landscape…

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

We reviewed data presented at the American Society of Hematology (ASH) conference in San Diego last week with a focus on the evolving treatment landscape for non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), myeloadysplastic syndrome (MDS) and acute myeloid leukemia (AML).Data on several novel programs were presented; we review select companies based on our standard abstract assessment methodology. We use our proprietary ranking methodology (PRM) to rank concerned abstracts on seven criteria…

We reviewed data presented at the American Society of Hematology (ASH) conference in San Diego last week with a focus on the evolving treatment landscape for non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), myeloadysplastic syndrome (MDS) and acute myeloid leukemia (AML).Data on several novel programs were presented; we review select companies based on our standard abstract assessment methodology. We use our proprietary ranking methodology (PRM) to rank concerned abstracts on seven criteria…

American Society of Hematology- (ASH) Annual Conference (2016) Review

With a focus on novel mechanisms of action (MoA), we highlight select non-Hodgkin's lymphoma (NHL) and Multiple Myeloma (MM) related abstracts at the upcoming American Society of Hematology (<a href="http://www.hematology.org/Annual-Meeting/" target="_blank">ASH – 2016</a>) conference in San Diego this weekend.We use our proprietary ranking methodology (PRM) to rank concerned abstracts on seven criteria (mechanism of action, clinical phase, indication, route of administration, study design, safety profile and efficacy profile) and assign weight to each criterion...

With a focus on novel mechanisms of action (MoA), we highlight select non-Hodgkin's lymphoma (NHL) and Multiple Myeloma (MM) related abstracts at the upcoming American Society of Hematology (ASH – 2016) conference in San Diego this weekend.We use our proprietary ranking methodology (PRM) to rank concerned abstracts on seven criteria (mechanism of action, clinical phase, indication, route of administration, study design, safety profile and efficacy profile) and assign weight to each criterion...

American Society of Hematology (ASH) -Annual Conference (2016) Preview

<ul>
<li>April saw dispersion re-expand, with median and mean widening modestly, confirming no systemic repricing of voting rights but renewed divergence across liquidity- and structure-driven dual-class pairs.</li>
<li>Convergence remained selective: Grifols, MFE and Sixt tightened, while Carlsberg, Fuchs and Handelsbanken re-widened, highlighting the episodic nature of ord/pref convergence.</li>
<li>Telecom Italia transitions towards corporate-action, while Nordic anomalies—particularly Handelsbanken—continue to dominate dispersion and constrain arbitrage.</li>
</ul>


April saw dispersion re-expand, with median and mean widening modestly, confirming no systemic repricing of voting rights but renewed divergence across liquidity- and structure-driven dual-class pairs.
Convergence remained selective: Grifols, MFE and Sixt tightened, while Carlsberg, Fuchs and Handelsbanken re-widened, highlighting the episodic nature of ord/pref convergence.
Telecom Italia transitions towards corporate-action, while Nordic anomalies—particularly Handelsbanken—continue to dominate dispersion and constrain arbitrage.


Liquid Universe of European Ordinary and Preferred Shares: April '26 Report

Spain

Grifols S.A. develops, manufactures, and markets plasma derivatives, IV Therapy, enteral nutrition, diagnostic systems, and medical materials.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Grifols SA (GRF SM)

Liquid Universe of European Ordinary and Preferred Shares: May '26 Report

European dual-class spreads tightened again in May as liquidity-driven convergence resumed. Handelsbanken, MFE and Telecom Italia led compression,...

Jesus Rodriguez Aguilar

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

AML represents one of the largest hematologic cancer populations with one of the worst survival rates. Global prevalence is expected to increase at...

Dion Stéfan Büchner M.D., FCAP

American Society of Hematology- (ASH) Annual Conference (2016) Review

We reviewed data presented at the American Society of Hematology (ASH) conference in San Diego last week with a focus on the evolving treatment...

Dion Stéfan Büchner M.D., FCAP

American Society of Hematology (ASH) -Annual Conference (2016) Preview

With a focus on novel mechanisms of action (MoA), we highlight select non-Hodgkin's lymphoma (NHL) and Multiple Myeloma (MM) related abstracts at...

Dion Stéfan Büchner M.D., FCAP

Liquid Universe of European Ordinary and Preferred Shares: April '26 Report

European dual-class spreads re-widened in April, with mean rising on right-tail moves. Liquidity-driven convergence persists, while structural...

Jesus Rodriguez Aguilar

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)